The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Characterization of Nanoparticles for Therapeutics
Abstract
Nanotechnology offers many advantages to traditional drug design, delivery and medical diagnostics; however, nanomedicines present considerable challenges for preclinical development. Nanoparticle constructs intended for medical applications consist of a wide variety of materials, and their small size, unique physicochemical properties and biological activity often require modification of standard characterization techniques. A rational characterization strategy for nanomedicines includes physicochemical characterization, sterility and pyrogenicity assessment, biodistribution (absorption, distribution, metabolism and excretion [ADME]) and toxicity characterization, which includes both in vitro tests and in vivo animal studies. Here, we highlight progress for a few methods that are uniquely useful for nanoparticles or are indicative of their toxicity or efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Polyethylenimine nanoparticles as efficient transfecting agents for mammalian cells
Nimesh, S., Goyal, A., Pawar, V., Jayaraman, S., Kumar, P., Chandra, R., Singh, Y. P., & Gupta, K. C. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.10.014 · Cited by 97
RetractedNanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles
Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7339 · Cited by 7,891
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“For example, certain nanoparticles can permeate the leaky vasculature surrounding tumors and areas of inflammation (through what is termed the enhanced permeability and retention [EPR] effect) and many nanoparticle-based anticancer drug strategies now exploit this ‘passive targeting’ mechanism to concentrate drugs in…”
BackgroundDrug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552 · cited 1×
“Furthermore, the nanoparticle formulations might have reduced side effects and improved efficacy because the nanoparticles ‘target’ the drug to the parts of the body where it is needed [2].”
BackgroundCurrent Protocols in Immunology
(2018) · Current Protocols in Immunology · doi:10.1002/(issn)1934-368x · Cited by 3,566
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Dynamic Light Scattering: With Applications to Chemistry, Biology, and Physics
Berne, B. J., & Pecora, R. (1976) · CERN Document Server (European Organization for Nuclear Research) · Cited by 2,856
Oberdörster, G., Maynard, A., Donaldson, K., Castranova, V., Fitzpatrick, J., Ausman, K., Carter, J., Karn, B., Kreyling, W., Lai, D., et al. (2005) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-2-8 · Cited by 2,134
Immunological properties of engineered nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.223 · Cited by 1,823 · cited 1×
“A comprehensive overview of nanoparticle interaction with the immune system is available in the literature [33].”
BackgroundSelf-citationGref, R., Lück, M., Quellec, P., Marchand, M., Dellacherie, E., Harnisch, S., Blunk, T., & Müller, R. H. (2000) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00156-3 · Cited by 1,723
Toxicity of Gold Nanoparticles Functionalized with Cationic and Anionic Side Chains
Goodman, C. M., McCusker, C. D., Yilmaz, T., & Rotello, V. M. (2004) · Bioconjugate Chemistry · doi:10.1021/bc049951i · Cited by 1,601
Decker, T., & Lohmann-Matthes, M.-L. (1988) · Journal of Immunological Methods · doi:10.1016/0022-1759(88)90310-9 · Cited by 1,359
Malik, N., Wiwattanapatapee, R., Klopsch, R., Lorenz, K., Frey, H., Weener, J. W., Meijer, E. W., Paulus, W., & Duncan, R. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00246-1 · Cited by 1,227
Nanotech approaches to drug delivery and imaging
Sahoo, S. K., & Labhasetwar, V. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02903-9 · Cited by 1,203
Noninvasive Imaging of Quantum Dots in Mice
Ballou, B., Lagerholm, B. C., Ernst, L. A., Bruchez, M. P., & Waggoner, A. S. (2004) · Bioconjugate Chemistry · doi:10.1021/bc034153y · Cited by 1,140
An enzyme-release assay for natural cytotoxicity
Korzeniewski, C., & Callewaert, D. M. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90438-6 · Cited by 1,076
Effect of single wall carbon nanotubes on human HEK293 cells
Cui, D., Tian, F., Ozkan, C. S., Wang, M., & Gao, H. (2005) · Toxicology Letters · doi:10.1016/j.toxlet.2004.08.015 · Cited by 831
Characterization of aqueous dispersions of Fe3O4 nanoparticles and their biomedical applications
Cheng, F.-Y., Su, C.-H., Yang, Y.-S., Yeh, C.-S., Tsai, C.-Y., Wu, C.-L., Wu, M.-T., & Shieh, D.-B. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.03.016 · Cited by 668
[60]Fullerene is a Powerful Antioxidant in Vivo with No Acute or Subacute Toxicity
Gharbi, N., Pressac, M., Hadchouel, M., Szwarc, H., Wilson, S. R., & Moussa, F. (2005) · Nano Letters · doi:10.1021/nl051866b · Cited by 656
Nanotechnology for the biologist
McNeil, S. E. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0205074 · Cited by 613
Self-citationPowers, K. W., Brown, S. C., Krishna, V. B., Wasdo, S. C., Moudgil, B. M., & Roberts, S. M. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj099 · Cited by 605
Hong, S., Bielinska, A. U., Mecke, A., Keszler, B., Beals, J. L., Shi, X., Balogh, L., Orr, B. G., Baker, J. R., & Banaszak Holl, M. M. (2004) · Bioconjugate Chemistry · doi:10.1021/bc049962b · Cited by 603
PATRI, A., KUKOWSKALATALLO, J., & BAKERJR, J. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.014 · Cited by 597
Self-citationSize-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles
Prabha, S., Zhou, W.-Z., Panyam, J., & Labhasetwar, V. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00315-0 · Cited by 553
Toxicology of ultrafine particles:in vivo studies
Oberdürster, G. (2000) · Philosophical Transactions of the Royal Society of London. Series A: Mathematical, Physical and Engineering Sciences · doi:10.1098/rsta.2000.0680 · Cited by 511
Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N. M., Alving, C. R., & Muggia, F. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg374 · Cited by 479
Complement activation and protein adsorption by carbon nanotubes
SALVADORMORALES, C., FLAHAUT, E., SIM, E., SLOAN, J., HGREEN, M., & SIM, R. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.02.006 · Cited by 434
In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers
Cagle, D. W., Kennel, S. J., Mirzadeh, S., Alford, J. M., & Wilson, L. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.5182 · Cited by 303
Schubert, M. A., & Müller-Goymann, C. C. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.03.006 · Cited by 297
Kobayashi, H., Kawamoto, S., Jo, S.-K., Bryant, H. L., Brechbiel, M. W., & Star, R. A. (2003) · Bioconjugate Chemistry · doi:10.1021/bc025633c · Cited by 262
Kainthan, R. K., Gnanamani, M., Ganguli, M., Ghosh, T., Brooks, D. E., Maiti, S., & Kizhakkedathu, J. N. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.06.021 · Cited by 250
Fang, J., Sawa, T., & Maeda, H. (2005) · Advances in Experimental Medicine and Biology · doi:10.1007/0-306-47932-x_2 · Cited by 221
Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake
Vonarbourg, A., Passirani, C., Saulnier, P., Simard, P., Leroux, J. C., & Benoit, J. P. (2006) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.30711 · Cited by 216
Bazile, D. V., Ropert, C., Huve, P., Verrecchia, T., Mariard, M., Frydman, A., Veillard, M., & Spenlehauer, G. (1992) · Biomaterials · doi:10.1016/0142-9612(92)90142-b · Cited by 200
In Vitro and In Vivo Evaluation of Oral Heparin–Loaded Polymeric Nanoparticles in Rabbits
Jiao, Y., Ubrich, N., Marchand-Arvier, M., Vigneron, C., Hoffman, M., Lecompte, T., & Maincent, P. (2002) · Circulation · doi:10.1161/hc0202.101988 · Cited by 200
Complement activation in factor D-deficient mice
Xu, Y., Ma, M., Ippolito, G. C., Schroeder, H. W., Carroll, M. C., & Volanakis, J. E. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261428398 · Cited by 198
Vittaz, M., Bazile, D., Spenlehauer, G., Verrecchia, T., Veillard, M., Puisieux, F., & Labarre, D. (1996) · Biomaterials · doi:10.1016/0142-9612(95)00322-3 · Cited by 193
Dutta, T., Agashe, H. B., Garg, M., Balasubramanium, P., Kabra, M., & Jain, N. K. (2007) · Journal of drug targeting · doi:10.1080/10611860600965914 · Cited by 157
3H Dendrimer Nanoparticle Organ/Tumor Distribution
Nigavekar, S. S., Sung, L. Y., Llanes, M., El-Jawahri, A. R., Lawrence, T. S., Becker, C. W., Balogh, L. P., & Khan, M. K. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000019302.26097.cc · Cited by 150
Interaction of PLGA nanoparticles with human blood constituents
Kim, D., El‐Shall, H., Dennis, D. M., & Morey, T. E. (2004) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2004.05.007 · Cited by 146
Ogawara, K., Yoshida, M., Higaki, K., Kimura, T., Shiraishi, K., Nishikawa, M., Takakura, Y., & Hashida, M. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00015-2 · Cited by 141
PEI-based vesicle-polymer hybrid gene delivery system with improved biocompatibility
Brownlie, A., Uchegbu, I. F., & Schätzlein, A. G. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.12.029 · Cited by 133
Lim, S., Lee, M., & Kim, C. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.032 · Cited by 128
Blood Compatibility of Cetyl Alcohol/Polysorbate-Based Nanoparticles
Koziara, J. M., Oh, J. J., Akers, W. S., Ferraris, S. P., & Mumper, R. J. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-7547-7 · Cited by 125
Szebeni, J., Baranyi, L., Sávay, S., Bodó, M., Milosevits, J., Alving, C. R., & Bünger, R. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00622.2005 · Cited by 113
Leroux, J., Gravel, P., Balant, L., Volet, B., Anner, B. M., Allémann, É., Doelker, É., & Gurny, R. (1994) · Journal of Biomedical Materials Research · doi:10.1002/jbm.820280410 · Cited by 94
Nanoparticle-mediated gene delivery: state of the art
Kumar, M., Hellermann, G., Lockey, R. F., & Mohapatra, S. S. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.8.1213 · Cited by 93
Measurement of Bacterial Ingestion and Killing by Macrophages
Campbell, P. A., Canono, B. P., & Drevets, D. A. (1994) · Current Protocols in Immunology · doi:10.1002/0471142735.im1406s12 · Cited by 82
PVP magnetic nanospheres: Biocompatibility, in vitro and in vivo bleomycin release
Ding, G., Kamulegeya, A., Chen, X., Jie, C., & Yinfeng, L. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.07.042 · Cited by 81
Craparo, E. F., Cavallaro, G., Bondı̀, M. L., Mandracchia, D., & Giammona, G. (2006) · Biomacromolecules · doi:10.1021/bm060570c · Cited by 73
Preclinical Characterization of Engineered Nanoparticles Intended for Cancer Therapeutics
Patri, A. K., Dobrovolskaia, M. A., Stern, S. T., & McNeil, S. E. (2006) · CRC Press eBooks · doi:10.1201/9781420006636-7 · Cited by 73
Self-citationSelf-assembled drug delivery systems
Jin, Y., Tong, L., Ai, P., Li, M., & Hou, X. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.11.025 · Cited by 67
Inhibition of malarial topoisomerase II in Plasmodium falciparum by antisense nanoparticles
Föger, F., Noonpakdee, W., Loretz, B., Joojuntr, S., Salvenmoser, W., Thaler, M., & Bernkop‐Schnürch, A. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.03.034 · Cited by 66
Furumoto, K., Nagayama, S., Ogawara, K., Takakura, Y., Hashida, M., Higaki, K., & Kimura, T. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.03.004 · Cited by 57
Ogawara, K., Furumoto, K., Takakura, Y., Hashida, M., Higaki, K., & Kimura, T. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00468-0 · Cited by 47
Sundstrom, J. B., Mao, H. Z., Santoianni, R. A., Villinger, F. J., Little, D. M., Huynh, T. T., Mayne, A. E., Hao, E., & Ansari, A. A. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200401010-00002 · Cited by 33
Ogawara, K., Yoshida, M., Kubo, J.-I., Nishikawa, M., Takakura, Y., Hashida, M., Higaki, K., & Kimura, T. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00121-2 · Cited by 28
Analysis of fullerene‐based nanomaterial in serum matrix by CE
Chan, K. C., Patri, A. K., Veenstra, T. D., McNeil, S. E., & Issaq, H. J. (2007) · Electrophoresis · doi:10.1002/elps.200600724 · Cited by 27
Self-citationPuzyr', A. P., Neshumaev, D. A., Вениаминовна, Т. С., Gv, M., Dolmatov, V. I., & Vs, B. (2005) · PubMed · Cited by 18
Preclinical Characterization of Engineered Nanoparticles Intended for Cancer Therapeutics
Stern, S. T., McNeil, S. E., Patri, A. K., & Dobrovolskaia, M. A. (2006) · CRC Press eBooks · doi:10.1201/9781420006636.ch7 · Cited by 13
Self-citation
Cited by
Zhang, X.-F., Liu, Z.-G., Shen, W., & Gurunathan, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091534 · Cited by 3,220
Batrakova, E. V., & Kabanov, A. V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.013 · Cited by 1,278
“Specific arrangements of polymeric molecules at the nanoscale achieved within such materials represent unique opportunities for safe and efficient delivery of drugs, genes, and imaging molecules [1-13].”
BackgroundDobrovolskaia, M. A., Aggarwal, P., Hall, J. B., & McNeil, S. E. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800032f · Cited by 1,022
Self-citationEffects of nanomaterial physicochemical properties on in vivo toxicity
Aillon, K. L., Xie, Y., El-Gendy, N., Berkland, C. J., & Forrest, M. L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.010 · Cited by 811
Techniques for physicochemical characterization of nanomaterials
Lin, P.-C., Lin, S., Wang, P. C., & Sridhar, R. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.11.006 · Cited by 708
Metadata
- Authors
- Hall, J. B., Dobrovolskaia, M. A., Patri, A. K., & McNeil, S. E.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2007-12
- Volume
- 2
- Issue
- 6
- Pages
- 789-803
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2135913252
- Cited by
- 409
- References
- 61
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.